Literature DB >> 21760601

Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?

Matthew R Weir1.   

Abstract

Glomerular filtration rate (GFR) acutely declines with the introduction of renin-angiotensin system inhibition. This response is functional, not anatomical, and varies with volume status. The reduction in GFR with renin-angiotensin system inhibition may serve as a biomeasure of future therapeutic benefit.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21760601     DOI： 10.1038/ki.2011.132

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  African Americans, hypertension and the renin angiotensin system.

Authors:  Sandra F Williams; Susanne B Nicholas; Nosratola D Vaziri; Keith C Norris
Journal:  World J Cardiol       Date:  2014-09-26

2.  Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.

Authors:  Ayako Sato; Hoglan Piao; Yukiko Nozawa; Tetsuo Morioka; Hiroshi Kawachi; Takashi Oite
Journal:  Clin Exp Nephrol       Date:  2012-02-11       Impact factor: 2.801

Review 3.  What should be the blood pressure target for patients with chronic kidney disease?

Authors:  Susanne B Nicholas; Nosratola D Vaziri; Keith C Norris
Journal:  Curr Opin Cardiol       Date:  2013-07       Impact factor: 2.161

4.  Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.

Authors:  Daishi Hirano; Saori Miwa; Daisuke Kakegawa; Chisato Umeda; Yoichi Takemasa; Ai Tokunaga; Kawakami Yuhei; Akira Ito
Journal:  Pediatr Nephrol       Date:  2021-01-19       Impact factor: 3.714

5.  Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Authors:  Sebastiaan Camiel Goulooze; Hiddo J L Heerspink; Martijn van Noort; Nelleke Snelder; Meike Brinker; Joerg Lippert; Thomas Eissing
Journal:  Clin Pharmacokinet       Date:  2022-05-05       Impact factor: 5.577

6.  Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.

Authors:  D Banerjee; P Winocour; T A Chowdhury; P De; M Wahba; R Montero; D Fogarty; A H Frankel; J Karalliedde; P B Mark; D C Patel; A Pokrajac; A Sharif; S Zac-Varghese; S Bain; I Dasgupta
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388

7.  Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-12

8.  Chapter 8: Future directions and controversies.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-12

9.  Chapter 6: Blood pressure management in children with CKD ND.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-12

10.  Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.

Authors:  Nelleke Snelder; Roland Heinig; Henk-Jan Drenth; Amer Joseph; Peter Kolkhof; Jörg Lippert; Dirk Garmann; Bart Ploeger; Thomas Eissing
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.